February 1, 2011
Bookmark and Share  



This week’s postings include:

February 2011 HCV Advocate newsletter that includes:

  • An article about the priority review given for boceprevir and telaprevir in the United States and the European Union.  In addition, telaprevir has been grant priority review in Canada.

  • “News Briefs” contains an overview of important news stories, including the first real collaboration between HCV pharmaceuticals, new guidelines on acetaminophen dosage, pilot programs for the HCV aged-based testing initiatives, and the use of medicines to prevent the recurrence of hepatitis C after liver transplantation. 

  • “HCV Snapshots” for February are devoted to research on the association between HCV, stroke and heart disease,

  • “HealthWise”’s topic this month is a further exploration of the heart and HCV

February HBV Journal Review that includes: 

  • A push to increase the diagnosis of liver cancer

  • A new and more accurate liver cancer marker

  • Early identification of liver cancer = longer survival

  • Women with HBV and Non-Hodgkin Lymphoma cancer

  • First-line of treatment – pegylated interferon or HBV antivirals?

  • Liver disease and risk of stroke

                      …..and many more articles


Don’t forget to check out our blog for more about the most recent news stories.





Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate www.hcvadvocate.org
Editor-in-Chief, HBV Advocate www.hbvadvocate.org


**Questions and Comments: Questions and/or comments can be directed to alanfranciscus@hcvadvocate.org

**To receive the eblast in your email inbox simply send an e-mail to: listserv@list.hcvadvocate.org with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.